Sunday, November 9, 2025
HomeNews

News

Boehringer Ingelheim support the potential use of nintedanib in children

Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents...

IMFINZI Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen

AstraZeneca’s IMFINZI (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)...

Zrou to Present Chinese Take on Plant-Based Food in Global Debut at Javits Center

YouKuai, the creators of Zrou, are the pioneers reshaping the landscape of plant-based cuisine in China. Now China’s leading plant-based meat brand plans to...

Avacta Announces AVA6000 Receives Orphan Drug Designation From the US FDA

Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION™ platforms, announces that...

Hornetsecurity Announces Strategic Growth Investment from TA

Hornetsecurity (the “Company”), a leading international cloud security and compliance SaaS provider, announced that TA Associates (“TA”), a leading global growth private equity firm,...
0FansLike
0FollowersFollow
spot_img

Hot Topics